

RealRate

PHARMACEUTICAL 2020











PHARMACEUTICAL 2020



ROCKET PHARMACEUTICALS INC. Rank 58 of 358



The relative strengths and weaknesses of ROCKET PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ROCKET PHARMACEUTICALS INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 69% points. The greatest weakness of ROCKET PHARMACEUTICALS INC. is the variable Other Liabilities, reducing the Economic Capital Ratio by 34% points.

The company's Economic Capital Ratio, given in the ranking table, is 207%, being 170% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	307,754
Cost of Goods Sold	0
Intangible Assets	30,815
Liabilities, Current	18,309
Liabilities, Non-Current	1,466
Other Assets	4,257
Other Compr. Net Income	147
Other Expenses	5,958
Other Liabilities	45,049
Other Net Income	1,425
Other Revenues	3,414
Property and Equipment	29,295
Research and Development	58,623
Selling, General and Administrative Expense	17,528

Output Variable	Value in 1000 USD
Assets	372,121
Liabilities	64,824
Expenses	82,109
Revenues	3,414
Stockholders Equity	307,297
Net Income	-77,270
Comprehensive Net Income	-77,196
Economic Capital Ratio	207%

